165 related articles for article (PubMed ID: 24312307)
1. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
PLoS One; 2013; 8(11):e81484. PubMed ID: 24312307
[TBL] [Abstract][Full Text] [Related]
2. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma.
Wagener N; Macher-Goeppinger S; Pritsch M; Hüsing J; Hoppe-Seyler K; Schirmacher P; Pfitzenmaier J; Haferkamp A; Hoppe-Seyler F; Hohenfellner M
BMC Cancer; 2010 Oct; 10():524. PubMed ID: 20920340
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
4. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker.
Lee HW; Choe M
Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604
[TBL] [Abstract][Full Text] [Related]
5. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma.
Xu ZQ; Zhang L; Gao BS; Wan YG; Zhang XH; Chen B; Wang YT; Sun N; Fu YW
Clin Transl Oncol; 2015 Jan; 17(1):41-9. PubMed ID: 24986100
[TBL] [Abstract][Full Text] [Related]
6. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance].
Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722
[TBL] [Abstract][Full Text] [Related]
7. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma.
Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C
J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140
[TBL] [Abstract][Full Text] [Related]
8. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer.
Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H
Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma.
Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS
J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma.
Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J
BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
He LJ; Cai MY; Xu GL; Li JJ; Weng ZJ; Xu DZ; Luo GY; Zhu SL; Xie D
Asian Pac J Cancer Prev; 2012; 13(7):3173-8. PubMed ID: 22994729
[TBL] [Abstract][Full Text] [Related]
12. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.
Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D
Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205.
Hirata H; Hinoda Y; Shahryari V; Deng G; Nakajima K; Tabatabai ZL; Ishii N; Dahiya R
Cancer Res; 2015 Apr; 75(7):1322-31. PubMed ID: 25600645
[TBL] [Abstract][Full Text] [Related]
15. High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma.
Eichenauer T; Simmendinger L; Fraune C; Mandelkow T; Blessin NC; Kluth M; Hube-Magg C; Möller K; Clauditz T; Weidemann S; Dahlem R; Fisch M; Riechardt S; Simon R; Sauter G; Büscheck F; Rink M
World J Urol; 2021 Feb; 39(2):481-490. PubMed ID: 32303902
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.
Hayashi A; Morikawa T; Kawai T; Kume H; Ishikawa S; Homma Y; Fukayama M
Virchows Arch; 2014 Apr; 464(4):463-71. PubMed ID: 24446035
[TBL] [Abstract][Full Text] [Related]
17. [Expression of enhancer of zeste homolog 2 in esophageal squamous cell carcinoma and its prognostic value in postoperative patients].
Wang H; Wang M; Lian G; Wu D
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jan; 33(1):99-102. PubMed ID: 23353165
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
19. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
20. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
